Business Update Positive

2026-07-27 10:54

- Management acknowledged Q1 FY27 as a soft/muted quarter due to timing shifts in customer deliveries, but expects stronger performance in Q2, Q3, and Q4, maintaining a full-year growth outlook in line with historical double-digit performance. - 60% of the full-year order book is already secured, providing strong visibility, and EBITDA and PAT margins are expected to remain intact for the full year. - Unit 4 expansion is underway with a capex outlay of approximately ₹1,200 crores for Phase 1 (FY27-FY28), adding 365 kiloliters of custom synthesis and 100 kiloliters of fermentation capacity by FY28; FY27 targeted capex is ₹700 crores. - The company has onboarded a new Big Pharma customer and is progressing on Semaglutide API, awaiting CDSCO approval, viewing it as a long-term robust opportunity. - Management is actively exploring use cases for Artificial Intelligence to optimize operations and contribute to innovation within the biotech pharma ecosystem.

Governance Positive

2026-07-24 16:08

- The 20th Annual General Meeting (AGM) was held on July 22, 2026. - All 8 resolutions proposed at the AGM were passed with requisite majority. - Key approvals included the adoption of the audited financial statements for FY ended March 31, 2026, declaration of dividend, re-appointment of directors and auditors, and approval of an upside sharing arrangement.

Governance Positive

2026-07-22 23:56

- The 20th Annual General Meeting (AGM) was held on July 22, 2026. - Members approved adoption of audited financial statements for FY2025-26, dividend declaration, re-appointment of directors, and appointment of statutory auditors. - Statutory Auditors' report for FY26 had no qualifications. All resolutions passed.

Business Update Neutral

2026-07-22 18:09

- Audio recording of the Earnings Call for the quarter ended June 30, 2026, held on July 22, 2026, is available on the company's website.

Financials Negative

2026-07-21 19:28

- Consolidated Revenue ₹4,182 Mn vs ₹5,402 Mn (▼22.6% YoY) - EBITDA ₹1,755 Mn vs ₹2,143 Mn (▼18.0% YoY) - PAT ₹1,199 Mn vs ₹1,358 Mn (▼11.7% YoY) - EBITDA Margin 39.6% vs 38.1% (▲150bps)

Financials Neutral

2026-07-21 16:55

- Consolidated Revenue ₹4,182 Mn vs ₹5,402 Mn (▲-22.6% YoY) - EBITDA ₹1,755 Mn vs ₹2,143 Mn (▲-18.1% YoY) - PAT ₹1,199 Mn vs ₹1,358 Mn (▲-11.8% YoY) - EBITDA Margin 39.6% vs 38.1% (▲154 bps)

Financials Negative

2026-07-21 16:47

- Consolidated Revenue ₹4,182.18 Mn vs ₹5,402.09 Mn (▼22.58% YoY) - EBITDA ₹1,754.55 Mn vs ₹2,143.04 Mn (▼18.13% YoY) - PAT ₹1,199.41 Mn vs ₹1,357.91 Mn (▼11.67% YoY) - EBITDA Margin 41.95% vs 39.67% (▲228bps)

Financials Negative

2026-07-21 16:38

- Consolidated Operating Revenue ₹418.22Cr vs ₹540.21Cr (▼22.58% YoY) - EBITDA ₹150.57Cr vs ₹191.49Cr (▼21.36% YoY) - PAT ₹119.94Cr vs ₹135.79Cr (▼11.67% YoY) - EBITDA Margin 36.00% vs 35.45% (▲55bps)

Business Update Neutral

2026-07-15 19:13

- Concall Schedule - Concall Date: Wednesday, July 22, 2026 - Concall Time: 11:30 AM IST

Routine Neutral

2026-07-14 19:04

New Filing detected. See link for details.

Governance Neutral

2026-07-08 12:14

- 20th Annual General Meeting (AGM) of Anthem Biosciences Limited is scheduled for Wednesday, July 22, 2026, at 03:30 P.M. IST via Video Conferencing/OAVM. - The Annual Report for FY 2025-26 is available via a provided web link and exact path. - Letters have been dispatched to shareholders with unregistered email addresses, providing instructions to access the Annual Report.

Financials Positive

2026-07-03 12:36

- ICRA upgraded Anthem Biosciences' long-term bank facility ratings from [ICRA]AA- (Positive) to [ICRA]AA (Stable). - This covers Fund-Based Working Capital (₹175 Cr), Term Loan (₹67.50 Cr), and Unallocated limits (₹23 Cr). - Short-term ratings ([ICRA]A1+) were reaffirmed.

Financials Positive

2026-06-30 23:05

- Annual Report for FY 2025-26 filed, detailing >15% Revenue growth and >30% EBITDA & PAT growth YoY. - 20th AGM to be held on July 22, 2026, 3:30 PM (IST). Plans include ₹1,200 Cr+ Unit IV expansion to double capacity.

Business Update Neutral

2026-06-30 22:37

- Anthem Biosciences Limited filed its Business Responsibility and Sustainability Report (BRSR) for FY 2025-26. - The company voluntarily undertook BRSR reporting for FY 2025-26, ahead of its applicability from FY 2026-27. - The report details the company's commitment to responsible business practices, sustainability, and enhanced stakeholder disclosures.

Financials Positive

2026-06-30 22:26

- Annual Report for FY 2025-26 enclosed. - 20th Annual General Meeting (AGM) to be held on Wednesday, July 22, 2026, at 3:30 PM (IST) via Video Conferencing (VC)/Other Audio-Visual Means (OAVM). - FY 2025-26 Key Financial Highlights (as per CEO's message): - Revenue from Operations: ₹2,124.3 Cr (▲>15% YoY) - EBITDA: ₹989.6 Cr (▲>30% YoY) - PAT: ₹591.8 Cr (▲>30% YoY) - EBITDA margins improved significantly.

Governance Positive

2026-06-30 22:18

- The 20th Annual General Meeting (AGM) of Anthem Biosciences Limited is scheduled for Wednesday, July 22, 2026, at 03:30 p.m. IST via Video Conferencing/OAVM. - The company has declared a final dividend for FY 2025-26, with the record date set for Friday, June 26, 2026. - Dividend payment will be made on or before Friday, August 21, 2026. - Key items on the agenda include adoption of financial statements, re-appointment of a director, appointment of statutory auditors (M/s. S.R. Batliboi & Associates LLP), and approval for continuation of an Independent Director (Mr. Ravikant Uppal) upon attaining 75 years of age.

Routine Neutral

2026-06-26 16:05

- Trading window for designated persons will be closed from July 01, 2026. - It will remain closed until 48 hours after the Board Meeting approves the financial results for the quarter ending June 30, 2026. - The date of the Board meeting will be informed in due course.

Ownership Negative

2026-06-19 15:11

- Aruna Ganesh, a member of the Promoter Group of Anthem Biosciences Limited, sold her entire shareholding of 1,71,14,604 equity shares. - This represents 3.05% of the paid-up equity share capital of the Company. - The transaction took place on June 18, 2026, and was disclosed under SEBI (Substantial Acquisition of Shares and Takeovers) Regulations.

Business Update Neutral

2026-06-05 17:13

- Investor Meet Schedule - Meeting Date: 10th June, 2026 - Meeting Type: Plant Visit & Group Meeting - Location: Bangalore - Mode: Physical

Business Update Neutral

2026-05-22 17:19

Anthem Biosciences Limited informed about its participation in upcoming analyst/institutional investor meetings. The company will attend the Nomura Investment Forum Asia 2026 in Singapore on June 2-3, 2026, and the Citi India Conference 2026 in Mumbai on June 4-5, 2026. Both events will feature one-on-one and group meetings. No unpublished price-sensitive information will be discussed during these interactions.

Business Update Positive

2026-05-22 15:46

Management highlighted a strong FY26 and record Q4, with aspirations for 20%+ long-term growth and maintaining high EBITDA margins (expected to continue at current levels, around 38-40% or higher). The company will invest approximately ₹1,200 crores in Capex over FY27-FY28 (₹700 Cr in FY27), primarily for Unit 4 expansion to double custom synthesis and increase fermentation capacity by 50%. Key growth drivers include investments in technology, expanding big pharma relationships, and a robust pipeline with 10 Phase 3 programs. Destocking is mostly complete, with positive future impact expected. Biotech funding is recovering, and recently commercialized molecules are contributing significantly.

Business Update Neutral

2026-05-20 18:11

Anthem Biosciences Limited announced the availability of the audio recording of the Earnings Call held on May 20, 2026, for the quarter and year ended March 31, 2026. The recording, which covers the Audited Standalone and Consolidated Financial Results, is accessible on the company's website.

Financials Positive

2026-05-19 21:06

Consolidated Revenue from Operations was ₹6,109 Mn vs ₹4,832 Mn (▲26.4% YoY), EBITDA was ₹3,184 Mn vs ₹2,092 Mn (▲52.2% YoY), PAT was ₹1,898 Mn vs ₹826 Mn (▲129.8% YoY). EBITDA Margin expanded to 48.1% from 43.29% (▲481bps). Management noted strong performance with the highest revenue quarter and expanded profitability margins.

Financials Positive

2026-05-19 20:23

Standalone Revenue ₹582.50 Cr vs ₹478.98 Cr (▲21.62% YoY), EBITDA ₹267.96 Cr vs ₹198.11 Cr (▲35.26% YoY), PAT ₹211.66 Cr vs ₹122.56 Cr (▲72.70% YoY). EBITDA Margin 46.00% vs 41.36% (▲464 bps). The board also recommended a final dividend of INR 2.00 per equity share for the financial year ended March 31, 2026.

Business Update Positive

2026-05-19 20:03

Anthem Biosciences disclosed Key Performance Indicators. For FY2026, total revenue grew 15.17% YoY to ₹21,243.33 million, EBITDA rose 31.21% to ₹8,971.69 million, and PAT increased 31.14% to ₹5,917.92 million. For the six months ended September 30, 2024, total revenue saw a significant 46.72% YoY increase to ₹8,635.50 million, EBITDA grew 47.86% to ₹3,275.04 million, and PAT surged 55.51% to ₹2,443.60 million, indicating strong recent performance.

Financials Positive

2026-05-19 19:57

Standalone Revenue ₹582.50 Cr vs ₹479.00 Cr (▲21.61% YoY), EBITDA ₹267.96 Cr vs ₹198.11 Cr (▲35.26% YoY), PAT ₹211.66 Cr vs ₹122.56 Cr (▲72.70% YoY). EBITDA Margin 46.00% vs 41.36% (▲464bps). The Board also recommended a final dividend of INR 2.00 per equity share for the financial year ended March 31, 2026.

Financials Positive

2026-05-19 19:51

Anthem Biosciences Limited's Audited Standalone Annual Results for FY26 show strong performance: Revenue from operations ₹2,089.31 Cr vs ₹1,840.65 Cr (▲13.51% YoY), EBITDA ₹827.11 Cr vs ₹689.01 Cr (▲20.04% YoY), PAT ₹670.56 Cr vs ₹506.19 Cr (▲32.48% YoY). EBITDA Margin expanded to 39.59% vs 37.43% (▲216 bps). The Board also recommended a final dividend of INR 2.00 per equity share and approved the re-appointment of internal and whole-time directors.

Financials Positive

2026-05-19 19:50

For the quarter ended March 31, 2026, Standalone Revenue ₹582.50 Cr vs ₹478.98 Cr (▲21.61% YoY), EBITDA ₹328.59 Cr vs ₹235.93 Cr (▲39.27% YoY), PAT ₹211.67 Cr vs ₹122.56 Cr (▲72.70% YoY). EBITDA Margin 56.41% vs 49.25% (▲716bps). The Board also recommended a final dividend of INR 2.00 per equity share for the financial year ended March 31, 2026.

Financials Positive

2026-05-19 19:47

Consolidated Revenue from Operations for Q4FY26 was ₹6,109 Mn vs ₹4,832 Mn (▲26.4% YoY). EBITDA was ₹3,184 Mn vs ₹2,092 Mn (▲52.2% YoY). PAT was ₹1,898 Mn vs ₹826 Mn (▲129.8% YoY). EBITDA Margin expanded to 48.1% from 43.3% (▲480bps) YoY. Management noted this was their highest revenue quarter ever and highlighted strong profitability and healthy financial position.

Financials Positive

2026-05-19 19:09

Consolidated Revenue ₹2,124.33Cr vs ₹1,844.55Cr (▲15.17% YoY), EBITDA ₹809.42Cr vs ₹670.84Cr (▲20.66% YoY), PAT ₹591.79Cr vs ₹451.26Cr (▲31.14% YoY). EBITDA Margin 38.10% vs 36.37% (▲173bps). The Board also recommended a final dividend of INR 2.00 per equity share for FY26 and approved the re-appointment of internal auditors and directors.

Financials Positive

2026-05-19 19:00

Anthem Biosciences Limited reported strong consolidated financial results for the quarter ended March 31, 2026. Consolidated Revenue stood at ₹610.94Cr compared to ₹483.20Cr (▲26.43% YoY), EBITDA at ₹319.41Cr compared to ₹209.25Cr (▲52.64% YoY), and PAT at ₹189.76Cr compared to ₹82.62Cr (▲129.67% YoY). EBITDA Margin expanded significantly to 52.28% from 43.31% (▲897bps). The Board also recommended a final dividend of INR 2.00 per equity share.

544449

Anthem Biosciences Ltd

Price Chart

Filing History

Unlock Full History